MedTrace Logo

A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa

NCT00782340 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 263

Last updated 2014-05-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see whether droxidopa is effective in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy, Parkinson's Disease), Non-diabetic neuropathy, or Beta Hydroxylase deficiency.

Conditions

  • Symptomatic Neurogenic Orthostatic Hypotension (NOH)
  • Non-diabetic Neuropathy
  • Primary Autonomic Failure
  • Dopamine Beta Hydroxylase Deficiency

Interventions

DRUG

Placebo

100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day

DRUG

Droxidopa

100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day

Sponsors & Collaborators

  • Chiltern International Inc.

    collaborator INDUSTRY

  • Chelsea Therapeutics

    lead INDUSTRY

Principal Investigators

  • Stephen Greer, MD · Arkansas Cardiology

  • Alberto Vasquez, MD · Suncoast Neuroscience

  • Richard Hull, MD · North Alabama Neuroscience

  • Brent Goodman, MD · Mayo Clinic

  • Alvin McElveen, MD · Bradenton Neurology, Inc

  • Mazen Dimachkie, MD · University of Kansas Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00782340 on ClinicalTrials.gov